↓ Skip to main content

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

Overview of attention for article published in Diagnostic Pathology, February 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
Published in
Diagnostic Pathology, February 2023
DOI 10.1186/s13000-023-01317-9
Pubmed ID
Authors

Kristýna Němejcová, Adam Šafanda, Michaela Kendall Bártů, Romana Michálková, Jana Drozenová, Pavel Fabian, Jitka Hausnerová, Jan Laco, Radoslav Matěj, Gábor Méhes, Petr Škapa, Ivana Stružinská, Pavel Dundr

Abstract

We examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis. Immunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test. We found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs. We provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 8%
Lecturer > Senior Lecturer 1 8%
Librarian 1 8%
Other 1 8%
Researcher 1 8%
Other 1 8%
Unknown 6 50%
Readers by discipline Count As %
Medicine and Dentistry 2 17%
Biochemistry, Genetics and Molecular Biology 1 8%
Unspecified 1 8%
Social Sciences 1 8%
Agricultural and Biological Sciences 1 8%
Other 0 0%
Unknown 6 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2023.
All research outputs
#18,936,243
of 23,467,261 outputs
Outputs from Diagnostic Pathology
#772
of 1,152 outputs
Outputs of similar age
#227,200
of 336,454 outputs
Outputs of similar age from Diagnostic Pathology
#9
of 18 outputs
Altmetric has tracked 23,467,261 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,152 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,454 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.